Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Astria Therapeutics, Inc. (ATXS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/08/2021 |
8-K
| Quarterly results |
| 06/02/2021 |
8-K
| Quarterly results |
| 01/29/2021 |
8-K
| Investor presentation|
Docs:
|
"Certificate of Designation of Series X Convertible Preferred Stock",
"Certificate of Designation of Series X Convertible Preferred Stock",
"STOCK PURCHASE AGREEMENT This Stock Purchase Agreement is dated as of January 28, 2021, by and among Catabasis Pharmaceuticals, Inc., a Delaware corporation , and each purchaser identified on Annex A hereto . BACKGROUND: A. The Company and each Purchaser is executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4 of the Securities Act , and Rule 506 of Regulation D as promulgated by the United States Securities and Exchange Commission under the Securities Act. B. The Purchasers, severally and not jointly, wish to purchase, and the Company wishes to issue and sell, upon the terms and conditions stated in this Agreement, an aggregate of 35,573 shares of Series X Convertible Preferred Stock, par value $0.001 per share , of the C...",
"Form of Registration Rights Agreement, by and among Catabasis Pharmaceuticals, Inc. and certain purchasers named therein",
"Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.",
"Presentation for investor conference call held by Catabasis Pharmaceuticals, Inc. on January 29, 2021" |
|
| 10/16/2019 |
8-K
| Investor presentation |
| 01/31/2017 |
8-K
| Form 8-K - Current report |
|
|